A review of techniques for difficult catheterisation and their costs

2021 ◽  
pp. 205141582110391
Author(s):  
Rion Healy ◽  
James Edward Dyer

Objective: Awareness of departmental expenditure gives surgeons the ability to make cost-effective decisions. We reviewed the available techniques for difficult catheterisation and assessed the cost of each method. Methods: A literature search was undertaken using EMBASE and Medline databases. Seven techniques for difficult catheterisation were identified, and a cost analysis was performed. All items required for a technique were costed per unit, including VAT, and can be referenced to the NHS supply chain. Results: Techniques were divided into three broad categories: simple urethral techniques – increased lubrication with different catheter sizes (£5.05) or types (£8.83 Tiemann tip, £10.65 Coude tip); complex urethral techniques – blind hydrophilic guidewire (£27.31), S-dilators (£244.62) and flexible cystoscopy (£38.78); and percutaneous techniques – suprapubic catheterisation (£117.38). Conclusion: This paper demonstrates a progression in cost and specialist input required when moving from simple urethral techniques to complex and percutaneous techniques. It is clear that clinicians should consider these cost implications and exhaust all simple techniques before moving to the more complex options. We would advocate the use of a national evidence-based difficult catheter algorithm to guide management based on both effectiveness and cost. Level of evidence: Not applicable.

2021 ◽  
Vol 27 (9) ◽  
pp. 1-9
Author(s):  
Isobel Clough

The NHS is facing an unprecedented backlog in both patient care and building maintenance, with severe implications for service delivery, finance and population wellbeing. This article is the first in a series discussing modular healthcare facilities as a potential solution to these issues, providing flexible and cost-effective spaces to allow services to increase capacity without sacrificing care quality. The first of three instalments, this paper will outline the problems facing the NHS estate, many of which have been exacerbated to critical levels by the COVID-19 pandemic, and what this means for service delivery. It will then make the case for modular infrastructure, outlining the potential benefits for healthcare services, staff and patients alike. Using modern methods of construction, this approach to creating physical space in healthcare can provide greater flexibility and a reduced impact on the environment. The next two articles in this series will go on to provide detailed case studies of successful modular implementation in NHS trusts, an analysis of the cost implications and guidance on the commissioning process and building a business case.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3128-3128
Author(s):  
Cecilia C. Yeung ◽  
Maggie A. Gama ◽  
Rodriguez Rafael ◽  
Edward C. Larkin ◽  
Kim Janatpour

Abstract Intro: Tonsillectomy is a common surgery for both adults and children. In children (under 18 years) the most common diagnosis is follicular hyperplasia. In adults (18 years and older) the most common neoplastic diagnosis is squamous cell carcinoma. Although a common fear of lymphoma involving the tonsils persist, the literature indicates non-Hodgkin lymphoma as the least common diagnosis among tonsillectomy specimens. The purpose of this study was to provide indications and guidelines to delineate a cost effective approach for selection of tonsils for lymphoma workup. At UC Davis Medical Center, if lymphoma is considered in the differential, the tonsil is processed through a lymphoma workup protocol; touch preps, flow cytometry, cytogenetics, electron microscopy, B5-fixed, and formalin-fixed tissue in paraffin. Tissue is frozen in liquid nitrogen and stored for possible future studies. This approach diminishes the possibility of a missed lymphoma diagnosis, however it is costly and labor intensive. The initial phase of our investigation involved the identification of worrisome clinical findings for comparison with our patient population. Next, we address the incidence of tonsillar lymphoma in children versus adults in our hospital because the two populations historically exhibit drastically different diagnoses. In the final phase of our investigation we address the cost effectiveness of our approach. Method: To define what clinical findings are worrisome, we performed a literature search of “tonsillectomy and lymphoma” on pubmed and revealed 60 articles dating back to 1980 with 22 articles selected for review. Next, we reviewed over 900 tonsillar specimens collected over five years at the Medical Center. This data was stratified with respect to age, diagnoses, and whether a lymphoma workup was performed. Data: Prominent worrisome clinical findings included: unilateral enlargement, rapidly growing tonsillar mass, and grossly asymmetric tonsils. The results of our specimen (UC Davis) review is included in the chart below. In 5 years lymphoma workups were performed in19 children and 42 adults. The cost of each workup was $4063.00 and Medicare reimburses $1180. Conclusion: The incidence of lymphoma in our pediatric population is 0 and in our adult population is less than 1%. The cost per lymphoma diagnosis in our pediatric population exceeds $77,197.00. In contrast, the cost per lymphoma diagnosis in our adult population is $21,330.00. This data in conjunction with our literature search leads us to recommend selecting specimens for lymphoma work up in both adults and pediatric patients with the clinical findings of unilateral growth, rapidly enlarging tonsillar mass, and grossly asymmetric tonsils as a criteria. Special consideration in the pediatric population should also include strong clinical suspicion for lymphoma prior to ordering a lymphoma workup due to an extremely low incidence. Tonsillar diagnoses in Children versus Adults Benign Lymphoma Other Neoplasm Children (n=372) 372 0 0 Adults (n=654) 572 8 82 Total (n=1034) 944 (91%) 8 (<1%) 82 (8%) Benign diagnoses include: follicular hyperplasia, benign mucosa and tonsillar tissue, amyloidosis, acute and chronic tonsillitis.Lymphoma diagnoses include: large B-cell , follicle center cell , and lymphoblastic lymphoma. Other Neoplasm diagnoses include: squamous cell and basal cell and metastatic adenocarcinoma, malignant spindle cell sarcoma.


2011 ◽  
Vol 93 (8) ◽  
pp. 576-582 ◽  
Author(s):  
Kapila Manikantan ◽  
Raghav C Dwivedi ◽  
Suhail I Sayed ◽  
KA Pathak ◽  
Rehan Kazi

Follow-up in head and neck cancer (HNC) is essential to detect and manage locoregional recurrence or metastases, or second primary tumours at the earliest opportunity. A variety of guidelines and investigations have been published in the literature. This has led to oncologists using different guidelines across the globe. The follow-up protocols may have unnecessary investigations that may cause morbidity or discomfort to the patient and may have significant cost implications. In this evidence-based review we have tried to evaluate and address important issues like the frequency of follow-up visits, clinical and imaging strategies adopted, and biochemical methods used for the purpose. This review summarises strategies for follow-up, imaging modalities and key investigations in the literature published between 1980 and 2009. A set of recommendations is also presented for cost-effective, simple yet efficient surveillance in patients with head and neck cancer.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 848-848 ◽  
Author(s):  
Salma Afifi ◽  
Nelly G. Adel ◽  
Elaine Duck ◽  
Sean M. Devlin ◽  
Heather Landau ◽  
...  

Abstract Background: Cyclophosphamide plus G-CSF (C+G-CSF) is the most widely used stem cell (SC) mobilization regimen in multiple myeloma (MM) patients. Plerixafor plus G-CSF (P+G-CSF) has demonstrated superior SC mobilization efficacy when compared to G-CSF alone in phase II and III studies and has been shown to rescue patients who fail mobilization with G-CSF with or without cyclophosphamide. Despite the proven efficacy of P+G-CSF in upfront SC mobilization, its use for this indication has been limited, mostly due to concerns of high cost of the drug. Investigators have proposed "on demand" use of plerixafor in patients identified to have inadequate SC mobilization with G-CSF with or without cyclophosphamide, with the assumption that such an approach promotes cost containment by limiting plerixafor use. However, a comprehensive comparison of the cost effectiveness of SC mobilization using C+G-CSF versus P+G-CSF has not been performed. The goal of this retrospective study was to conduct a cost analysis between these two approaches. Methods: Using the pharmacy database, we identified all MM patients treated at Memorial Sloan Kettering Cancer Center between 11/2008 and 6/2012 who received C+G-CSF or P+G-CSF for upfront SC mobilization. Patients collecting <5 x 106 CD34+ cells/kg were considered mobilization failures and had a second attempt at SC mobilization using an alternative approach. For salvage mobilization, patients received P+G-CSF after failing C+G-CSF-based mobilization or were re-mobilized with C+G-CSF along with plerixafor after failing upfront P+G-CSF mobilization. Mobilization costs included in the analysis were those associated with upfront mobilization, those associated with salvage mobilization in patients failing an initial mobilization, and those associated with complications directly related to the mobilization procedures. Cost calculations included the following: cost of cyclophosphamide 3000 mg/m2, plerixafor 0.24 mg/kg, and G-CSF 10 mcg/kg and their administration prior to and during pheresis sessions; pheresis sessions; laboratory tests on pheresis days; re-hospitalization occurring within 15 days of either mobilization approach and considered directly related to the mobilization procedure. All costs were calculated using the institution’s ratio of cost to charges, and were normalized and adjusted based on institutional charges and costs for 2012. Results: A total of 223 patients undergoing upfront mobilization were identified, with 111 patients receiving C+G-CSF, and 112 patients receiving P+G-CSF. Thirteen patients (12%) were re-hospitalized due to C+G-CSF-related complications, with an average hospital stay of 6.5 days. No patients in the P+G-CSF arm were hospitalized. Nineteen patients (17%) in the C+G-CSF group failed first mobilization and received P+G-CSF as salvage regimen, with four (3.6%) failing salvage collection and ultimately deemed collection failures. Seven patients (6.2%) in the P+G-CSF group failed upfront mobilization and received C+G-CSF along with plerixafor as salvage regimen, with two (1.8%) subsequently failing salvage mobilization. The average number of pheresis sessions performed was 3.29 and 2.42 in the C+G-CSF and P+G-CSF upfront groups, respectively (p=0.373). In total, the average cost of stem cell collection per patient was 1.3 times greater in the C+G-CSF group than in the P+GCSF upfront group (p=0.017). When the costs associated with salvage pheresis are discounted for the 19 patients in the C+G-CSF upfront group who failed first SC mobilization, assuming that these patients could have been salvaged by plerixafor-on-demand, the cost per patient in the C+G-CSF group remains 1.26 times greater (p=0.019) than that of the P+G-CSF group. Conclusion: The use of P+G-CSF upfront for SC mobilization is more cost effective than the more widely used approach employing C+G-CSF. This difference is likely due to several factors including: 1) higher rate of hospitalization in the C+G-CSF group due to expected complications such as febrile neutropenia and catheter-related infections; 2) higher rate of mobilization failure leading to increased need for salvage mobilization in the C+G-CSF group; 3) reduced G-CSF use in the upfront P+G-CSF group. Overall, this single institution study provides additional rationale for the standard use of P+G-CSF as upfront mobilization regimen in MM patients. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 45 (10) ◽  
pp. 1083-1086 ◽  
Author(s):  
Paul H. C. Stirling ◽  
Nicholas D. Clement ◽  
Paul J. Jenkins ◽  
Andrew D. Duckworth ◽  
Jane E. McEachan

The United Kingdom National Institute for Health and Care Excellence considers a procedure to be cost-effective if the cost per quality-adjusted life year gained falls below a threshold of £20,000–£30,000 (€22,600–33,900; US$24,600–$36,900). This study used cost per quality-adjusted life year methodology to determine the cost-utility ratio of A1 pulley release. Pre- and postoperative EuroQol 5 Dimensions 5 Likert scores were collected prospectively over 6 years from 192 patients. The median pre- and postoperative indices derived from the EuroQol 5 Dimensions 5 Likert scores were significantly different at 0.77 and 0.80. The mean life expectancy was 21 years. The mean number of quality-adjusted life years gained was 1 per patient. The mean cost-utility ratio per patient was £32,308 (€36,508; US$39,730) and £16,154 (€18,254; US$19,869) at 1 and 2 years, respectively. Provided the benefit of surgery was maintained over the remaining life expectancy, the cost-utility ratio decreased to £1537 (€1737; US$1891) per patient. A1 pulley release is cost-effective provided the benefit is maintained for 2 years. The procedure is also associated with a statistically significant improvement in quality of life. Level of evidence: III


2021 ◽  
Vol 4 (2) ◽  
pp. 10-15
Author(s):  
Abdulla Turdiev ◽  
◽  
Sanjar Akmalov

This article examines the cost structure of the enterprise, the cost structure that makes up the production cost of the product (works, services). As a result of the research, proposals were developed to optimize the cost of the product. In particular, the use of modern innovative technologies in all processes of production and improvement of production; extensive use of local, cheap and quality raw materials in the production of products; increase labor productivity and improve the skills of employees using skilled labor in production; the need to reduce transportation and sales costs by improving the supply chain has been suggested in the study


Author(s):  
Luqman Raji ◽  
Zhigilla Y.I ◽  
Wadai J

Nigeria is one of developing countries in the world that experience shortage of electricity for her economic and social development. In Nigeria, most of the small-scale industries use diesel/petrol-based systems to generate their electricity. However, due to the cost fluctuation of oil and gas fuel, an alternative power generation should be considered. This paper targets to examine the cost analysis of system for supplying electricity to LUMATEC Aluminium products shop in Mubi, Adamawa state Nigeria. Hybrid Optimization Model for Electric Renewable (HOMER) is used as a tool for cost analysis. The scenario consider in this study was only stand-alone with battery system. Results revealed that the system have 10kW PV with cost of electricity (COE) of $0.312/kW. The initial capital cost and total net present cost (NPC) are $21.775 and $26.148 respectively, with payback period of 5.8years. In conclusion, this study provides the solution of power supply to the small-scale industries at cost effective and available throughout the year and it is feasible to solve the small-scale industries, rural and urban electricity supplying in this country (Nigeria). It is recommended that Nigerian Government & Law makers should promotes the use of standalone PV system for domestic and small-scale industry by providing financial assistance through soft loans, subsides and grants.


Paradigm ◽  
2005 ◽  
Vol 9 (2) ◽  
pp. 86-95
Author(s):  
V.K. Khanna

Waves of liberalization are sweeping all over the world breaking political barriers, integrating world capital and financial markets, opening up international trade and freeing import of technology or raw materials from licenses. New challenges and opportunities have been thrown up. The new economic scenario has also brought in risks of increased competition. As the customer is supreme, only those enterprises are going to be successful, which are able to provide goods and services to the customer in a timely cost-effective manner and also provide quality, which not only satisfies him but delights him. This means that the enterprise has to manage its operations in such a way that the production costs and delivery costs are kept to the minimum and margins are optimized. Simultaneously, it has to build a culture of quality and productivity because without that it is just not possible to survive. Finally, to stay always one step ahead of the competition, there has to be an element of creativity. Advance Product Quality Planning and Production Part Approval Process help the organization to be creative and innovative in approach in addressing all customers' related issues. Both these tools are very important while implementing quality management system requirements pertaining to ISO/TS 16949:2002. These tools are generic in nature and can help any type of industry. Effective implementation of PPAP will help the supply chain to improve the quality of the product, reduce the cost by optimal use of resources and maintain on time delivery at competitive cost.


2018 ◽  
Vol 1 (1) ◽  
pp. e3-e16 ◽  
Author(s):  
Yih Chyn Phan ◽  
Jonathan Cobley ◽  
Wasim Mahmalji

Introduction Isiris α™ (Coloplast®) is an innovative single-use disposable flexible cystoscope with an integrated ureteric stent grasper designed specifically to remove ureteric stents. It allows clinicians to remove ureteric stents easily on the wards or in clinics without the need of arranging a routine and dedicated flexible cystoscopy appointment for patients. We evaluated Isiris α’s practical use and cost analysis against traditional reusable endoscopes. Method We compared the cost of removing ureteric stents using Isiris α™ in 10 patients prospectively versus traditional flexible cystoscopes in 10 patients retrospectively. The costs of the equipment, medications, reprocess machines, and utility costs were consulted from the relevant departments and companies. As for labour cost, we have sourced British Medical Association (BMA) and Royal College of Nursing (RCN) websites. Results From our study, it costs £260.65 and £123.41 on average to remove a ureteric stent using Isiris α™ and traditional flexible cystoscope respectively (p<0.001). Stent removal in the endoscopy department was delayed in 60% of patients, on average 6.4 days, compared to 0% of patients using Isiris α™ (p = 0.048). Conclusion Although Isiris α™ is shown to be a more expensive option to remove ureteric stents based on our analysis, it still provides clinicians flexibility and ease in removing ureteric stents in the outpatient clinic, reducing the pressure and demand for dedicated flexible cystoscopy slots in the endoscopy department.


Author(s):  
Samantha Reese ◽  
Margaret Mann ◽  
Timothy Remo ◽  
Kelsey Horowitz

Bottoms-up cost analysis has been a mainstay of commoditized industry and manufacturing processes for years, however a holistic objective supply chain analysis to inform research and investment in the development of early stage technologies has not. The potential for rapid adoption of wide bandgap (WBG) semiconductors, specifically silicon carbide (SiC), highlights a need to understand the drivers of location-specific manufacturing cost, global supply chains, and plant location decisions. Further, ongoing research and investment, necessitates analytical analysis to help inform the roadmap of SiC technologies. In collaboration with PowerAmerica the project explores the bottoms-up cost analysis of wafers, devices, modules, and variable frequency motor drives at the anticipated manufacturing levels. Leveraging these models, it outlines how the cost reduction potential of proposed research advances can be quantified.


Sign in / Sign up

Export Citation Format

Share Document